IMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces an Investigation of Regulus Therapeutics Inc. and Encourages Investors with Losses to Contact the Firm

IRVINE, CA / ACCESSWIRE / February 3, 2017 / Khang & Khang LLP (the “Firm”) announces that it is investigating claims against Regulus Therapeutics Inc. (“Regulus” or the “Company”) (Nasdaq: RGLS) concerning possible violations of federal securities laws.

If you purchased shares of Regulus, and want more information free of charge, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or by e-mail at joon@khanglaw.com.

On June 27, 2016, the Company confirmed that it was contacted by the U.S. Food and Drug Administration (“FDA”) that its new drug to treat the chronic hepatitis C virus infection will be put on clinical hold due to a second incidence of jaundice. On January 27, 2017, post-market, Regulus disclosed that the FDA would not negotiate the clinical hold on RG-101 until the agency confirms receipt of the last safety and efficacy information from continued clinical and pre-clinical studies.

When this information was released to the investing public, shares of Regulus fell, causing investors serious harm.

If you have any questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or by e-mail at joon@khanglaw.com.

This press release may constitute Attorney Advertising in some jurisdictions.

Contacts

Joon M. Khang, Esq.

Telephone: 949-419-3834

Facsimile: 949-225-4474

joon@khanglaw.com

SOURCE: Khang & Khang LLP

ReleaseID: 454213